New Hydrogel Device Receives FDA Approval for Bleeds
The FDA approved a hydrogel system for peripheral arterial bleeds, offering a new tool for patients with small vessel injuries.
Updated on Oct. 31, 2026 in Stroke
Live Poll
Do you trust that new medical device approvals adequately prioritize long-term patient safety?
The U.S. FDA approved the Embrace Hydrogel Embolic System to treat peripheral arterial bleeds in vessels up to 6 mm in diameter. This provides a new interventional option for patients requiring vessel occlusion.
Why it matters
The approval expands treatment options for managing arterial bleeding, allowing physicians to address vessels slightly larger than those covered by the device's previous tumor-related indication. This update broadens the clinical utility of the hydrogel-based technology in interventional procedures.
In the 130-patient HALT trial conducted across 22 U.S. sites, researchers reported 100% freedom from major adverse events and 90% clinical success through 30 days. Long-term outcomes beyond the 30-day window remain under study.
The players
U.S. Food and Drug Administration
The federal agency responsible for evaluating the safety and efficacy of medical devices before they reach the U.S. market.
Instylla, Inc.
A Burlington, Massachusetts-based medical technology company focused on developing hydrogel-based embolic systems.
The details
The device utilizes a water-based polyethylene glycol hydrogel that forms a rapid, sustained occlusion upon contact with blood within the vessel. Designed for precision, the system maintains microcatheter access during the procedure to allow for adjustments. The hydrogel is engineered to liquify via hydrolysis over approximately 11 months, allowing the body to absorb the material over time.
Timeline
2017: Instylla, Inc. was founded.
August 2025: FDA granted initial premarket approval for tumor embolization.
October 31, 2026: FDA approved the device for peripheral arterial bleeds.
Health Landscape
This approval represents an expansion of the Embrace Hydrogel Embolic System, which received initial regulatory clearance for hypervascular tumor embolization in 2025. It reflects a broader trend toward using resorbable, hydrogel-based technologies to achieve targeted vessel occlusion.
Patients with conditions requiring arterial embolization may see this device offered by their interventional radiologist as a new therapeutic option. If you are facing a procedure involving vessel occlusion, it is worth discussing the specific techniques and materials your specialist recommends.
The takeaway
This new approval adds a resorbable hydrogel option for physicians performing peripheral artery embolization. Patients should always consult with their vascular specialist or interventional radiologist about the most appropriate tools and techniques for their specific clinical situation.
Further reading
Learn more about the latest innovations in Stroke management and clinical interventions.
Source note: This article includes information reported by Pharmabiz.
Live Poll
Do you trust that new medical device approvals adequately prioritize long-term patient safety?
